Misonix (NASDAQ:MSON) announced its earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01, Morningstar.com reports. The business had revenue of $9.56 million during the quarter. Misonix had a negative net margin of 18.10% and a negative return on equity of 29.13%.
Shares of Misonix stock opened at $22.38 on Friday. Misonix has a fifty-two week low of $11.67 and a fifty-two week high of $22.38.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc raised its position in shares of Misonix by 15.7% during the 3rd quarter. Vanguard Group Inc now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after buying an additional 28,889 shares in the last quarter. Wells Fargo & Company MN raised its position in Misonix by 1,487.5% in the 3rd quarter. Wells Fargo & Company MN now owns 6,350 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 5,950 shares during the period. Nordea Investment Management AB purchased a new stake in Misonix in the 3rd quarter worth about $649,000. Vanguard Group Inc. raised its position in Misonix by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock worth $3,941,000 after purchasing an additional 28,889 shares during the period. Finally, Renaissance Technologies LLC raised its position in Misonix by 10.8% in the 3rd quarter. Renaissance Technologies LLC now owns 231,899 shares of the medical equipment provider’s stock worth $4,290,000 after purchasing an additional 22,599 shares during the period. 21.17% of the stock is owned by institutional investors and hedge funds.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Recommended Story: Consumer Price Index (CPI)
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.